Home / Sell by State / New York
New York · Sell-Side M&A
New York runs one of the strictest corporate-practice-of-medicine regimes in the country. A non-physician cannot own your practice, so the value a buyer can acquire sits in the management company, not the clinical entity. That structure is exactly where value is won or lost. We represent New York owners only, and we build the deal around the rules instead of around the buyer.
A confidential ballpark in under two minutes, no email required.
New York's Real Differentiator
New York enforces the corporate practice of medicine doctrine among the most strictly of any state. A non-physician individual or company cannot own a medical practice, cannot employ physicians to deliver care, and cannot profit directly from running a medical business. Only a licensed physician can own and run the clinical practice. That single rule is why a New York sale is never an off-the-shelf company purchase, and why structure decides whether your deal closes and at what price.
The lawful path is a professional corporation or PLLC, owned by a licensed New York physician, that holds the clinical practice and employs the clinicians, paired with a management services organization that provides non-clinical business services for a fee. The MSO is what a non-physician buyer actually owns and capitalizes, and it is kept aligned to the PC through a stock transfer restriction agreement.
Business Corporation Law Section 1507 limits PC share ownership to licensed professionals. LLC Law Section 1207(b) requires every member of a professional LLC to hold a New York medical license. Education Law Section 6512(1) makes unlicensed practice a Class E felony, the enforcement teeth behind the doctrine. Cited here per the Lengea Law explainer, not raw statute text.
New York regulates the MSO management fee. Fees tied to a percentage of patient or clinical revenue can constitute prohibited fee-splitting under New York law, and the Department of Health monitors MSO arrangements for corporate-practice violations. The economics that flow to the MSO, the thing being bought, must be structured to survive that review.
A New York sale to a PE or strategic buyer is almost always a recapitalization of, or asset sale into, an MSO plus a friendly-PC reorganization, not a simple stock sale of the practice. Getting the structure right before going to market is the single biggest lever you control.
Statute citations come from a healthcare-law-firm explainer (Lengea Law), consistent with a second independent explainer (Zivian Health), not a direct read of the raw statute text. Treat as accurate as of June 2026. Sources: Lengea Law and Zivian Health corporate-practice-of-medicine analyses (linked in our sources).
| Measure | Figure | Note |
|---|---|---|
| New York population | ~19.9M | Fourth-most populous US state |
| State-level med spa count | Not published | AmSpa reports national totals only |
| US med spas (national total) | 10,488 | AmSpa 2024 report |
AmSpa's State of the Medical Spa Industry report publishes a national med spa count only and includes no state-by-state breakdown or ranking. Population figure is a US Census Bureau estimate.
Market Reality
AmSpa's State of the Medical Spa Industry report publishes a national med spa count only, with no state-by-state breakdown or ranking, so we will not cite an uncitable New York figure. What is verifiable is scale: New York is the fourth-most populous state in the country at roughly 19.9 million residents. That standing shows up in deals: in February 2025 a PE-backed platform entered New York by acquiring a two-location Manhattan med spa, and a New York-founded dermatology group has grown into the largest practice in its Northeast region. That is the consolidation demand a New York seller is sitting on.
Run my numbers →See Your Number First
A confidential ballpark in under two minutes. No email required to see your range. The estimate is generated on your device. Nothing is stored or sent unless you choose to continue.
Step 1 · Instant ballpark
Estimated enterprise value
Practices like yours trade around 2.6x – 5.3x adjusted earnings.
What raises your number
What lowers your number
Step 2 · What you receive when you continue
Your custom valuation report. Comparable transactions, your likely buyer pool, and timing analysis.
Your buyer-readiness scorecard. The specific moves that raise your multiple before you go to market.
A confidential 30-minute strategy call with Bill Walker. No obligation, no pressure.
Your information is never shared, and we have never broken a client's confidentiality.
Estimate only. A ballpark from limited inputs plus published industry M&A benchmarks.
What Moves Value Here
No New York-specific sale multiple is published, and we will not invent one. The honest anchor is the national vertical range already on our med spa, cosmetic dermatology, and plastic surgery hubs. What changes a New York seller's realized value is how the deal has to be built: value sits in the MSO, and how cleanly that management company clears state review decides what a buyer will actually pay.
Most of the enterprise value a non-physician buyer can acquire is the management company, not the professional corporation. A buyer pays for the MSO's defensible cash flow and the durability of the PC relationship. A practice already cleanly split into a compliant MSO transacts faster and holds its value.
Map my structure →New York's limits on percentage-of-revenue management fees mean deals are valued on defensible MSO cash flow, not on top-line clinical revenue. A fee structure exposed to fee-splitting review invites re-trading and discounts. Clean it up before market.
See the rules →New York, and New York City in particular, is one of the highest-demand aesthetic markets in the country. Stronger buyer competition for well-run, compliant platforms supports the national range. It does not create a published state multiple.
Who is buying →We reference the national vertical multiple range published on our practice-type hubs. We do not publish a New York-specific multiple, because none exists in a citable, defensible form. In New York, value is moved more by structure and compliance readiness than by geography. Your real range comes from a confidential, practice-specific analysis of your earnings, your MSO structure, and your comps.
Who Is Actually Buying in New York
A New York seller does not depend on one local acquirer. Well-capitalized national platforms and PE-backed MSOs buy here, and there are documented, in-state proof points. Schweiger Dermatology Group is headquartered and was founded in New York City, is PE-backed, and runs more than 120 offices. AYA Medical Spa, backed by Eagle Merchant Partners, entered New York in February 2025 by acquiring a two-location Manhattan med spa. We will never name a "local buyer" that does not exist.
Detail bars are redacted by design. Every name and activity claim on this board is published from verifiable records; anything beyond the public record stays confidential.
Schweiger (NYC HQ, PE-backed) and AYA / Eagle Merchant (Manhattan acquisition, Feb 2025) are the in-state proof points, documented via BBB, BusinessWire, and PRNewswire. Forefront Dermatology and the broader 35-plus PE-backed platform count are named as national consolidators active in the dermatology and aesthetics vertical, per Practical Dermatology's M&A market coverage. No local-only buyer is asserted.
New York Sale FAQ
Not directly. New York enforces the corporate practice of medicine doctrine strictly, so a non-physician individual or company cannot own a medical practice, employ physicians to deliver care, or profit directly from running a medical business. The lawful path is the friendly-PC and MSO model: a professional corporation or PLLC owned by a licensed New York physician holds the clinical practice and employs the clinicians, and a separate management services organization, the part a non-physician investor owns and funds, contracts to provide non-clinical services such as billing, HR, real estate, marketing, and admin for a fee. The MSO is the entity that can be bought and sold, so a New York sale is a structured transaction, not a simple stock sale of the practice.
In practice, yes, if your buyer is a private equity firm or a non-physician platform. Because New York reserves practice ownership for licensed professionals, most enterprise value a non-physician buyer can acquire sits in the management company, not the professional corporation. A physician seller who has not separated the business into a clean PC and MSO structure has a deal-readiness gap that suppresses both buyer interest and price. Getting the structure right before going to market is the single biggest lever a New York seller controls, and it is one of the first things we map.
Per a healthcare-law explainer from Lengea Law, the core anchors are New York Business Corporation Law Section 1507, which restricts professional corporation share ownership to licensed professionals only, New York Limited Liability Company Law Section 1207(b), which requires every member of a professional LLC to hold a New York medical license, and New York Education Law Section 6512(1), which makes the unlicensed practice of a profession a Class E felony and provides the enforcement teeth behind the doctrine. The doctrine is rooted broadly in New York Education Law reserving the practice of medicine for licensed professionals. We cite the law-firm explainer here rather than the raw statute text.
No. There is no published New York-specific multiple, and we will not quote one. What we use is the national vertical range for your practice type, then we explain how New York law and market move structure and value. In New York, value sits in the MSO, not the professional corporation, and the management fee has to be structured to survive state review of fee-splitting. A practice that is already cleanly separated into a compliant MSO, with a defensible management agreement, transacts faster and holds its value. Your real number comes from a confidential, practice-specific analysis.
Demand is national and verifiably present in New York. Schweiger Dermatology Group is headquartered in New York City, was founded in New York, is private-equity backed with capital led by LLR Partners, and operates more than 120 offices across the Northeast, describing itself as the largest dermatology practice in the New York, New Jersey, Pennsylvania, and Connecticut region. In February 2025, AYA Medical Spa, backed by Atlanta private equity firm Eagle Merchant Partners, entered New York by acquiring Tribeca MedSpa, a two-location Manhattan med spa. The accurate picture is well-capitalized national platforms and PE-backed MSOs buying in New York, not a single local-only acquirer.
New York is one of the largest aesthetic markets in the country. AmSpa’s State of the Medical Spa Industry report publishes a national med spa count only, with no state-by-state breakdown or ranking, so we will not cite an uncitable New York figure. What is verifiable is scale: New York is the fourth-most populous state in the country, with roughly 19.9 million residents per US Census Bureau estimates, anchored by the largest metro area in the country, which is exactly why it is one of the highest-demand aesthetic markets in the country.
Match Your Practice Type
How recurring and membership revenue, provider capacity, and key-person risk set a med spa's value, paired with the New York structure work above.
Med spa sell-side →Where New York's largest in-state derm activity is happening, and how a cosmetic derm practice is valued for sale.
Cosmetic derm sell-side →The valuation and deal-structure work for a surgical aesthetic practice, mapped to New York's corporate-practice rules.
Plastic surgery sell-side →By Metro
Compare every market on the Sell by State directory.
New York City deal activity plus the local enforcement reality every NYC seller faces.
Selling in New York City →
Who you work with
Bill Walker founded Aesthetic Brokers after leading mergers and acquisitions for a large private-equity-backed healthcare services organization. Before that he flew for the Marine Corps at the Presidential Helicopter Squadron and commanded a squadron in combat. He knows how an investor values a practice, and how to make sure that value lands with you, not the buyer.
Talk with Bill about your practiceStart with a confidential, two-minute read on where you stand.
